Compile Data Set for Download or QSAR
maximum 50k data
Found 1278 with Last Name = 'davenport' and Initial = 'r'
TargetCatechol O-methyltransferase(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019329(CHEMBL1089318)
Affinity DataKi:  1nMAssay Description:Inhibition of catalytic activity of human cloned COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liq...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCatechol O-methyltransferase(Rattus norvegicus (Rat))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019329(CHEMBL1089318)
Affinity DataKi:  1.5nMAssay Description:Inhibition of catalytic activity of rat COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liquid scint...More data for this Ligand-Target Pair
TargetCatechol O-methyltransferase(Mus musculus)
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019329(CHEMBL1089318)
Affinity DataKi:  1.5nMAssay Description:Inhibition of catalytic activity of mouse COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liquid sci...More data for this Ligand-Target Pair
TargetCatechol O-methyltransferase(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019331(CHEMBL3289430)
Affinity DataKi:  6.30E+3nMAssay Description:Inhibition of catalytic activity of human cloned COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liq...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCatechol O-methyltransferase(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019333(CHEMBL3289432)
Affinity DataKi:  7.90E+3nMAssay Description:Inhibition of catalytic activity of human cloned COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liq...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCatechol O-methyltransferase(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019332(CHEMBL3289431)
Affinity DataKi:  2.50E+4nMAssay Description:Inhibition of catalytic activity of human cloned COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liq...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCatechol O-methyltransferase(Mus musculus)
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019331(CHEMBL3289430)
Affinity DataKi:  6.30E+4nMAssay Description:Inhibition of catalytic activity of mouse COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liquid sci...More data for this Ligand-Target Pair
TargetCatechol O-methyltransferase(Rattus norvegicus (Rat))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019331(CHEMBL3289430)
Affinity DataKi:  1.58E+5nMAssay Description:Inhibition of catalytic activity of rat COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liquid scint...More data for this Ligand-Target Pair
TargetCatechol O-methyltransferase(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50019330(CHEMBL3289429)
Affinity DataKi:  2.51E+5nMAssay Description:Inhibition of catalytic activity of human cloned COMT expressed in Escherichia coli using [3H]-S-adenosylmethionine as substrate after 20 mins by liq...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251680(US10100018, Example 16 | US9464060, 16)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251680(US10100018, Example 16 | US9464060, 16)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243822((S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)...)
Affinity DataIC50:  2nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243737((S)-2-(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-e...)
Affinity DataIC50:  2nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243738((S)-2-(2-Methylsulfanyl-3-oxo-spiro[3.5]non-1-en-1...)
Affinity DataIC50:  2nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  3nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243758((S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)...)
Affinity DataIC50:  3nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243759((S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)...)
Affinity DataIC50:  3nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  3nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243736((S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)...)
Affinity DataIC50:  3nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-4(Homo sapiens (Human))
Ucb Pharma

Curated by ChEMBL
LigandPNGBDBM50243823((S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)...)
Affinity DataIC50:  3nMAssay Description:Inhibition of integrin alpha4beta1 receptor in human whole blood by flow cytometryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D(Homo sapiens (Human))
Celltech R&D

Curated by ChEMBL
LigandPNGBDBM50219014(CHEMBL149559)
Affinity DataIC50:  3.70nMAssay Description:Inhibition of human phosphodiesterase 4 from U937 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US10100018, Example 65 | US9464060, 65)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US10100018, Example 65 | US9464060, 65)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US10100018, Example 61 | US9464060, 61)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US10100018, Example 61 | US9464060, 61)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1278 total ) | Next | Last >>
Jump to: